Developer docs
API playgroundTry for free, no card

Search company profiles

USC Stem Cell

Full company profile

uuid005dluy

Namestring
USC Stem Cell
Legal namestring
University of Southern California
Company typeenum
Private
Founded yearint
2006
Descriptiontext

USC Stem Cell is the umbrella designation for three interlinked entities at the University of Southern California: the Department of Stem Cell Biology and Regenerative Medicine within the Keck School of Medicine, the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research (established in 2006 with a $20 million gift from Eli and Edythe Broad), and a university-wide initiative connecting over 100 research and clinical faculty across USC and Children's Hospital Los Angeles. The center runs six clinical translation programs covering heart regeneration, kidney building from stem cells, neurodegeneration and blindness treatment, cancer immunotherapy, bone/joint healing, and HIV gene therapy cure. Core technology platforms include embryonic and induced pluripotent stem cells, CRISPR-based gene editing, organoid engineering, synthetic cellular communication systems (synNotch), and the only known ES-cell-derived knockout rat models. Research is supported by core facilities for flow cytometry, optical imaging, and therapeutic screening serving approximately 100 laboratories.

The business model is that of an academic research department rather than a commercial entity. Revenue sources are competitive research grants (CIRM, NIH, ARPA-H, private foundations), philanthropic gifts, tuition from undergraduate, master's, PhD, and postdoctoral training programs, fee-for-service use of core research facilities, and technology licensing income. Notable spinouts include AcuraStem (ALS therapy licensed to Takeda), AO Technologies (ARPA-H-funded cochleoscope startup), and Carthronix (osteoarthritis cartilage regeneration). The center operates from the Eli and Edythe Broad Center at 1975 Zonal Ave., Los Angeles, and is led by Department Chair and Center Director Charles (Chuck) Murry, who succeeded founder Andrew McMahon.

Short descriptiontext

USC Stem Cell is an academic research department and center within USC's Keck School of Medicine that conducts stem cell biology and regenerative medicine research across six clinical translation areas, trains undergraduate through postdoctoral students, and spins out startups such as AcuraStem and AO Technologies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine research, stem cell biology education, clinical translation programs, gene editing therapeutics, academic biomedical training
Industry7 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAJ
Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYEDAHABAC
Health & Biomedical Research Universities (Academic Medical Center–Affiliated)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Educational Support Services61171
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Health Services8000
Product category
Academic Regenerative Medicine Research
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Research Grants and Funding
TypeLicensing Royalties
Description

As an academic research center, USC Stem Cell primarily operates through competitive research grants from government agencies and foundations including CIRM, NIH, and private foundations. Funding supports specific research programs and clinical translation initiatives.

stemcell.keck.usc.edu
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of developed technologies and therapies to pharmaceutical companies. Takeda licensed AcuraStem's PIKFYVE ASO technology for ALS treatment.

stemcell.keck.usc.edu
3Startup Formation
TypeLicensing Royalties
Description

Formation of startups from research discoveries including AO Technologies (ARPA-H funded), AcuraStem, Carthronix for commercialization of therapeutic innovations.

stemcell.keck.usc.edu
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Infrastructure, Operations
Pricing details1 tier
1Master's Program in Stem Cell Biology and Regenerative Medicine - one-year MS program
ModelSubscriptionBilling cadenceAnnual
Notes

The one-year Master of Science program offers courses in cutting-edge biomedical science including tuition-based graduate education. Specific tuition rates are managed by USC Office of Admissions.

stemcell.keck.usc.edu
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

USC Stem Cell is the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, functioning as a department, research center, and university-wide initiative. It delivers multidisciplinary education programs (undergraduate minor, MS, PhD, postdoctoral), operates shared research facilities (flow cytometry, optical imaging, therapeutic screening), and conducts clinical translation research across cancer immunotherapy, synthetic kidney engineering, gene editing for HIV, neurodegeneration/blindness treatments, and musculoskeletal regeneration. The center also licenses developed technologies to pharmaceutical companies and runs the USC+CHLA Alpha Clinic for cell and gene therapy delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • First embryonic stem cell-based knockout rats created for disease modeling
+3 more records
Product overview1 text field

USC Stem Cell is an academic department and research center offering multidisciplinary educational programs and cutting-edge stem cell research. It encompasses the Department of Stem Cell Biology and Regenerative Medicine, the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, and a university-wide initiative connecting over 100 research faculty. The organization provides undergraduate, master's, PhD, and postdoctoral training programs, operates core research facilities (Flow Cytometry, Optical Imaging, Therapeutic Screening), and conducts clinical translation research across multiple therapeutic areas including cancer immunotherapy, synthetic kidney development, gene editing, neurodegeneration/blindness treatment, and musculoskeletal regeneration. Key programs include the USC+CHLA Alpha Clinic for cell therapy delivery and the USC Center for Stem Cell Engineering for disease mechanism research.

Product and service9 records
1Stem Cell Biology and Regenerative Medicine Education Programs
2Core Research Facilities (Flow Cytometry, Optical Imaging, Therapeutic Screening)
3Cancer Immunotherapy Research Program
CategoryClinical Translation Research
Description

Research program developing renewable sources of immune cells (macrophages and granulocytes) engineered to attack cancer and infections.

4Synthetic Kidney Building Program
CategoryClinical Translation Research
Description

Research program working to build synthetic kidneys grown from human stem cells, including assembloid technology combining kidney filtering and urine-concentrating components.

5Gene Editing for HIV and Disease Treatment
CategoryClinical Translation Research
Description

Gene editing technology research including CRISPR-based approaches for curing HIV/AIDS and developing treatments for diseases ranging from diabetes to cancer.

6Neurodegeneration and Blindness Treatment Research
CategoryClinical Translation Research
Description

Clinical translation research including stem cell-based treatments for macular degeneration and ALS, including retina-supporting cell patches and antisense oligonucleotide therapies.

7Musculoskeletal Regeneration Program
CategoryClinical Translation Research
Description

Research program developing cartilage regeneration therapies for osteoarthritis, sports injuries using stem cell-based cartilage implants (Plurocart), and 3D scaffold approaches for craniosynostosis treatment.

8USC+CHLA Alpha Clinic
CategoryClinical Services
Description

A collaborative cell and gene therapy clinic between USC and Children's Hospital Los Angeles for accelerating the delivery of these therapies to patients.

9USC Center for Stem Cell Engineering
CategoryResearch Center
Description

A collaboration between the Keck School of Medicine of USC and the USC Viterbi School of Engineering focused on using stem cell engineering to uncover disease mechanisms and advance new therapies.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

USC Stem Cell initiative connects over 100 research and clinical faculty across USC and Children's Hospital Los Angeles. Multiple joint programs including USC+CHLA Alpha Clinic for cell therapies, shared faculty appointments, and collaborative research across pediatric and adult medicine.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

City of Hope conducted clinical trial for HIV/AIDS patients based on USC researcher Paula Cannon's discoveries. Also partnered with Mark Humayun's team for macular degeneration clinical trials using stem cell-based retina implants.

Strategic tierMajorTypeTechnology or Integration
Description

Licensed AcuraStem's PIKFYVE inhibiting antisense oligonucleotide (ASO) technology for ALS treatment. Takeda is moving the spinal injection therapy into clinical trials after AcuraStem (founded by Justin Ichida) developed the treatment.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborative partner with USC, UC Santa Barbara, City of Hope, and Caltech on stem cell-based clinical trials for macular degeneration using retina-supporting cells on surgical implant patches.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborative partner in Mark Humayun's macular degeneration stem cell therapy team, contributing to the interdisciplinary approach combining medicine, engineering, and biology.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic partner in stem cell-based macular degeneration treatment research alongside USC, UCSB, City of Hope, and Regenerative Patch Technologies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

International collaboration with Toshio Miki's team for extracorporeal liver support system development, with additional support from Germany's Federal Ministry for Education and Research (BMBF).

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Philanthropically funded research division focused on cell biology and iPSC-based disease modeling. Comparable in its use of stem cell-derived models and technology platforms, but with a narrower focus on cell science rather than therapeutic translation.

2Stanford Institute for Stem Cell Biology and Regenerative Medicine
TypeDirect peer
Description

Stanford's flagship academic stem cell research institute within the School of Medicine. Directly comparable in mission, structure, and translational scope (basic to clinical) and serves as one of the main competitors for talent and grant funding.

TypeDirect peer
Description

Pediatric hospital-affiliated stem cell research center with strengths in developmental biology and cell therapy. Comparable in clinical translation focus, particularly through the affiliated Alpha Clinic model.

TypeDirect peer
Description

Harvard University-wide stem cell research initiative connecting faculty across multiple schools and hospitals. Mirrors USC Stem Cell's university-wide collaborative model and competes for the same faculty, trainees, and federal funding.

TypeOthers
Description

Startup-stage clinical-stage company developing stem cell-based retinal implants for macular degeneration. Directly comparable as a commercialization vehicle for USC's stem cell-derived retina patch technology and a clinical-stage partner.

TypeRegional player
Description

Los Angeles-based affiliated medical center with a regenerative medicine institute that is a joint recipient of the LA Claude D. Pepper Older Americans Independence Center with USC. Highly comparable in regional research collaboration and translational orientation.

TypeDirect peer
Description

La Jolla-based independent research institute with a long history in stem cell and regenerative biology. Comparable in scale of research faculty and emphasis on discovery science feeding into translational pipelines.

TypeDirect peer
Description

Independent stem cell research institute operating its own laboratories and disease-focused programs. Comparable in dedicated stem cell mission and translational pipeline, though operationally structured as a private research institute rather than a university department.

TypeDirect peer
Description

San Francisco-based independent biomedical research institute with substantial stem cell, iPSC, and regenerative medicine programs. Closely comparable as a Bay Area academic-adjacent research enterprise with strong translation focus.

TypeDirect peer
Description

UCSF's regenerative medicine center running a similar portfolio of iPSC, organoid, and clinical translation programs. Shares the Eli and Edythe Broad-named naming convention and is a leading direct comparator on scientific output.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

USC Stem Cell

Academic Regenerative Medicine Researchstemcell.keck.usc.edu

USC Stem Cell is an academic research department and center within USC's Keck School of Medicine that conducts stem cell biology and regenerative medicine research across six clinical translation areas, trains undergraduate through postdoctoral students, and spins out startups such as AcuraStem and AO Technologies.

What USC Stem Cell does

USC Stem Cell is the umbrella designation for three interlinked entities at the University of Southern California: the Department of Stem Cell Biology and Regenerative Medicine within the Keck School of Medicine, the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research (established in 2006 with a $20 million gift from Eli and Edythe Broad), and a university-wide initiative connecting over 100 research and clinical faculty across USC and Children's Hospital Los Angeles. The center runs six clinical translation programs covering heart regeneration, kidney building from stem cells, neurodegeneration and blindness treatment, cancer immunotherapy, bone/joint healing, and HIV gene therapy cure. Core technology platforms include embryonic and induced pluripotent stem cells, CRISPR-based gene editing, organoid engineering, synthetic cellular communication systems (synNotch), and the only known ES-cell-derived knockout rat models. Research is supported by core facilities for flow cytometry, optical imaging, and therapeutic screening serving approximately 100 laboratories.

The business model is that of an academic research department rather than a commercial entity. Revenue sources are competitive research grants (CIRM, NIH, ARPA-H, private foundations), philanthropic gifts, tuition from undergraduate, master's, PhD, and postdoctoral training programs, fee-for-service use of core research facilities, and technology licensing income. Notable spinouts include AcuraStem (ALS therapy licensed to Takeda), AO Technologies (ARPA-H-funded cochleoscope startup), and Carthronix (osteoarthritis cartilage regeneration). The center operates from the Eli and Edythe Broad Center at 1975 Zonal Ave., Los Angeles, and is led by Department Chair and Center Director Charles (Chuck) Murry, who succeeded founder Andrew McMahon.

USC Stem Cell firmographics

Firmographics
Name
USC Stem Cell
Legal name
University of Southern California
Website
https://stemcell.keck.usc.edu
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
USC Stem Cell is an academic research department and center within USC's Keck School of Medicine that conducts stem cell biology and regenerative medicine research across six clinical translation areas, trains undergraduate through postdoctoral students, and spins out startups such as AcuraStem and AO Technologies.
Ownership category
akta.pro rank

USC Stem Cell industry classification

Industry
Product category
Academic Regenerative Medicine Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Educational Support Services (61171)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAJ
Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYEDAHABAC
Health & Biomedical Research Universities (Academic Medical Center–Affiliated)

Keywords

  • Regenerative medicine research
  • Stem cell biology education
  • Clinical translation programs
  • Gene editing therapeutics
  • Academic biomedical training

Where USC Stem Cell is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

USC Stem Cell business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

  1. Research Grants and Funding: As an academic research center, USC Stem Cell primarily operates through competitive research grants from government agencies and foundations including CIRM, NIH, and private foundations. Funding supports specific research programs and clinical translation initiatives.
  2. Technology Licensing: Licensing of developed technologies and therapies to pharmaceutical companies. Takeda licensed AcuraStem's PIKFYVE ASO technology for ALS treatment.
  3. Startup Formation: Formation of startups from research discoveries including AO Technologies (ARPA-H funded), AcuraStem, Carthronix for commercialization of therapeutic innovations.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualMaster's Program in Stem Cell Biology and Regenerative Medicine - one-year MS program

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

USC Stem Cell product offering

Product offering

Core offering

USC Stem Cell is the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, functioning as a department, research center, and university-wide initiative. It delivers multidisciplinary education programs (undergraduate minor, MS, PhD, postdoctoral), operates shared research facilities (flow cytometry, optical imaging, therapeutic screening), and conducts clinical translation research across cancer immunotherapy, synthetic kidney engineering, gene editing for HIV, neurodegeneration/blindness treatments, and musculoskeletal regeneration. The center also licenses developed technologies to pharmaceutical companies and runs the USC+CHLA Alpha Clinic for cell and gene therapy delivery.

Product overview

USC Stem Cell is an academic department and research center offering multidisciplinary educational programs and cutting-edge stem cell research. It encompasses the Department of Stem Cell Biology and Regenerative Medicine, the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, and a university-wide initiative connecting over 100 research faculty. The organization provides undergraduate, master's, PhD, and postdoctoral training programs, operates core research facilities (Flow Cytometry, Optical Imaging, Therapeutic Screening), and conducts clinical translation research across multiple therapeutic areas including cancer immunotherapy, synthetic kidney development, gene editing, neurodegeneration/blindness treatment, and musculoskeletal regeneration. Key programs include the USC+CHLA Alpha Clinic for cell therapy delivery and the USC Center for Stem Cell Engineering for disease mechanism research.

Differentiator

Problem solved

Functional benefit

Products and services

  • Stem Cell Biology and Regenerative Medicine Education Programs
  • Core Research Facilities (Flow Cytometry, Optical Imaging, Therapeutic Screening)
  • Cancer Immunotherapy Research Program Research program developing renewable sources of immune cells (macrophages and granulocytes) engineered to attack cancer and infections.
  • Synthetic Kidney Building Program Research program working to build synthetic kidneys grown from human stem cells, including assembloid technology combining kidney filtering and urine-concentrating components.
  • Gene Editing for HIV and Disease Treatment Gene editing technology research including CRISPR-based approaches for curing HIV/AIDS and developing treatments for diseases ranging from diabetes to cancer.
  • Neurodegeneration and Blindness Treatment Research Clinical translation research including stem cell-based treatments for macular degeneration and ALS, including retina-supporting cell patches and antisense oligonucleotide therapies.
  • Musculoskeletal Regeneration Program Research program developing cartilage regeneration therapies for osteoarthritis, sports injuries using stem cell-based cartilage implants (Plurocart), and 3D scaffold approaches for craniosynostosis treatment.
  • USC+CHLA Alpha Clinic A collaborative cell and gene therapy clinic between USC and Children's Hospital Los Angeles for accelerating the delivery of these therapies to patients.
  • USC Center for Stem Cell Engineering A collaboration between the Keck School of Medicine of USC and the USC Viterbi School of Engineering focused on using stem cell engineering to uncover disease mechanisms and advance new therapies.

Quantifiable outcome

  • First embryonic stem cell-based knockout rats created for disease modeling
  • +3 more outcomes

Companies that use USC Stem Cell

Customer profile

Named customers5 records

Segments7 records

Ideal customer profiles4 records

USC Stem Cell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

USC Stem Cell partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and minor.

  • Children's Hospital Los Angeles (CHLA)coreStrategic or Co-development PartnerUSC Stem Cell initiative connects over 100 research and clinical faculty across USC and Children's Hospital Los Angeles. Multiple joint programs including USC+CHLA Alpha Clinic for cell therapies, shared faculty appointments, and collaborative research across pediatric and adult medicine.
  • City of HopemajorStrategic or Co-development PartnerCity of Hope conducted clinical trial for HIV/AIDS patients based on USC researcher Paula Cannon's discoveries. Also partnered with Mark Humayun's team for macular degeneration clinical trials using stem cell-based retina implants.
  • Takeda Pharmaceutical CompanymajorTechnology or IntegrationLicensed AcuraStem's PIKFYVE inhibiting antisense oligonucleotide (ASO) technology for ALS treatment. Takeda is moving the spinal injection therapy into clinical trials after AcuraStem (founded by Justin Ichida) developed the treatment.
  • Regenerative Patch TechnologiesmajorStrategic or Co-development PartnerCollaborative partner with USC, UC Santa Barbara, City of Hope, and Caltech on stem cell-based clinical trials for macular degeneration using retina-supporting cells on surgical implant patches.
  • UC Santa Barbara (UCSB)majorStrategic or Co-development PartnerCollaborative partner in Mark Humayun's macular degeneration stem cell therapy team, contributing to the interdisciplinary approach combining medicine, engineering, and biology.
  • CaltechmajorStrategic or Co-development PartnerAcademic partner in stem cell-based macular degeneration treatment research alongside USC, UCSB, City of Hope, and Regenerative Patch Technologies.
  • Charité University BerlinminorStrategic or Co-development PartnerInternational collaboration with Toshio Miki's team for extracorporeal liver support system development, with additional support from Germany's Federal Ministry for Education and Research (BMBF).

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

USC Stem Cell competitors and assessment

Company assessment

Emerging players

  • Allen Institute for Cell Science: Philanthropically funded research division focused on cell biology and iPSC-based disease modeling. Comparable in its use of stem cell-derived models and technology platforms, but with a narrower focus on cell science rather than therapeutic translation.

Direct peers

  • Stanford Institute for Stem Cell Biology and Regenerative Medicine: Stanford's flagship academic stem cell research institute within the School of Medicine. Directly comparable in mission, structure, and translational scope (basic to clinical) and serves as one of the main competitors for talent and grant funding.
  • Cincinnati Children's Center for Stem Cell Biology: Pediatric hospital-affiliated stem cell research center with strengths in developmental biology and cell therapy. Comparable in clinical translation focus, particularly through the affiliated Alpha Clinic model.
  • Harvard Stem Cell Institute: Harvard University-wide stem cell research initiative connecting faculty across multiple schools and hospitals. Mirrors USC Stem Cell's university-wide collaborative model and competes for the same faculty, trainees, and federal funding.
  • Salk Institute for Biological Studies: La Jolla-based independent research institute with a long history in stem cell and regenerative biology. Comparable in scale of research faculty and emphasis on discovery science feeding into translational pipelines.
  • New York Stem Cell Foundation Research Institute: Independent stem cell research institute operating its own laboratories and disease-focused programs. Comparable in dedicated stem cell mission and translational pipeline, though operationally structured as a private research institute rather than a university department.
  • Gladstone Institutes: San Francisco-based independent biomedical research institute with substantial stem cell, iPSC, and regenerative medicine programs. Closely comparable as a Bay Area academic-adjacent research enterprise with strong translation focus.
  • UCSF Broad Center for Regeneration Medicine and Stem Cell Research: UCSF's regenerative medicine center running a similar portfolio of iPSC, organoid, and clinical translation programs. Shares the Eli and Edythe Broad-named naming convention and is a leading direct comparator on scientific output.

Others

  • Regenerative Patch Technologies: Startup-stage clinical-stage company developing stem cell-based retinal implants for macular degeneration. Directly comparable as a commercialization vehicle for USC's stem cell-derived retina patch technology and a clinical-stage partner.

Regional players

  • Cedars-Sinai Regenerative Medicine Institute: Los Angeles-based affiliated medical center with a regenerative medicine institute that is a joint recipient of the LA Claude D. Pepper Older Americans Independence Center with USC. Highly comparable in regional research collaboration and translational orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

USC Stem Cell social profiles

Digital presence

USC Stem Cell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

USC Stem Cell leadership team

Management profile

Number of profiles

Profiles10 records

USC Stem Cell funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

USC Stem Cell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about USC Stem Cell

What does USC Stem Cell do?

USC Stem Cell is the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, functioning as a department, research center, and university-wide initiative. It delivers multidisciplinary education programs (undergraduate minor, MS, PhD, postdoctoral), operates shared research facilities (flow cytometry, optical imaging, therapeutic screening), and conducts clinical translation research across cancer immunotherapy, synthetic kidney engineering, gene editing for HIV, neurodegeneration/blindness treatments, and musculoskeletal regeneration. The center also licenses developed technologies to pharmaceutical companies and runs the USC+CHLA Alpha Clinic for cell and gene therapy delivery.

Is USC Stem Cell a public or private company?

USC Stem Cell is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was USC Stem Cell founded?

USC Stem Cell was founded in 2006. It employs 11 to 50 people.

Where is USC Stem Cell based?

USC Stem Cell is headquartered in Los Angeles, United States, in the North America region.

How does USC Stem Cell make money?

Three revenue lines are on record. Research Grants and Funding is the primary driver. The others are technology Licensing and startup Formation.

Who are USC Stem Cell's main competitors?

Allen Institute for Cell Science is listed as an emerging player. Direct peers are Stanford Institute for Stem Cell Biology and Regenerative Medicine, Cincinnati Children's Center for Stem Cell Biology, Harvard Stem Cell Institute, Salk Institute for Biological Studies, New York Stem Cell Foundation Research Institute, Gladstone Institutes and UCSF Broad Center for Regeneration Medicine and Stem Cell Research. Regenerative Patch Technologies is listed as an others. Cedars-Sinai Regenerative Medicine Institute is listed as a regional player.

Does USC Stem Cell have an API?

No public API is recorded for USC Stem Cell.

What industry is USC Stem Cell in?

USC Stem Cell's product category is Academic Regenerative Medicine Research. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalCIRM grant funds new stem cell therapy to heal heartsCIRM awarded $6.9 million to USC Stem Cell scientists for preclinical development of a stem-cell therapy to regenerate heart muscle after a severe heart attack. Clinical trials targeting late 2027 will test safety and feasibility, with sites at USC and the University of Washington. The therapy aims to be off-the-shelf, scalable, and accessible to underrepresented populations.News-MedicalNew method generates renewable supply of progenitor immune cellsA USC Stem Cell-led team published in Cell a method to expand granulocyte-monocyte progenitors (GMPs) long-term in the lab, enabling engineering for immunotherapy. The engineered GMPs, carrying chimeric antigen receptors, delayed disease in mice with blood cancer and solid tumors, and restored immune function in a mouse model of chronic granulomatous disease.Neuroscience NewsAdult Neurogenesis Fuels Verbal Learning and MemoryResearchers from USC Stem Cell and the USC Neurorestoration Center discovered that adult neurogenesis directly supports verbal learning and memory in humans, a finding distinct from visuospatial learning observed in animal models. The study analyzed brain tissue from epilepsy patients and found that cognitive decline in these areas correlates with a dramatic slowdown in new brain cell production during the first 20 years of the disease. These insights suggest potential therapeutic avenues, such as exercise or drugs, to boost neurogenesis and improve cognitive function in conditions like Alzheimer’s and aging.UscUSC Stem Cell welcomes new leader, renowned physician-scientist Chuck MurryCharles Murry has been appointed as the new head of USC Stem Cell, succeeding Andrew McMahon, to lead the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine. Murry brings extensive experience from the University of Washington and previous industry leadership at Sana Biotechnology, aiming to accelerate translational research in heart disease. This leadership change is part of a strategic effort to expand the center's research impact and clinical partnerships within the Los Angeles region.UscUSC Stem Cell research from Justin Ichida’s lab advances toward clinical development for ALS, following a license agreement between companies Takeda and AcuraStemTakeda and AcuraStem have entered into a license agreement to advance stem cell research from Justin Ichida’s lab at USC toward clinical development for amyotrophic lateral sclerosis (ALS). This partnership enables the commercialization of discoveries made in the university lab, marking a significant step for the startup co-founded by Ichida. The deal positions the potential treatment to move forward with a reputable biopharmaceutical partner.